Critical Therapeutics, Inc. Completes Phase II Clinical Trial for Zileuton Injection

LEXINGTON, Mass.--(BUSINESS WIRE)--Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced top-line results from its Phase II clinical trial of the injectable formulation of zileuton (zileuton injection), the Company’s investigational compound for acute asthma in the emergency department (ED). The clinical trial was designed to explore the pulmonary function profile, safety, tolerability and pharmacokinetic profile of zileuton injection.